Market Analysis and Price Projections for NDC 23155-0832: Hydralazine Hydrochloride
Overview of NDC 23155-0832
The National Drug Code (NDC) 23155-0832 corresponds to Hydralazine Hydrochloride, a medication manufactured and distributed by Heritage Pharmaceuticals Inc., doing business as Avet Pharmaceuticals Inc.[5].
Drug Description and Use
Hydralazine Hydrochloride is a vasodilator used primarily in the treatment of high blood pressure (hypertension) and in certain cases of heart failure. It works by relaxing the muscles in the blood vessels, which helps to lower blood pressure and improve blood flow.
Market Context
Pharmaceutical Market Trends
The pharmaceutical market, particularly the segment involving generic and branded cardiovascular medications, is subject to various trends and regulatory changes. The biopharma and biotech industries are experiencing rapid growth, driven by technological advancements, evolving regulatory frameworks, and a shift towards patient-centered care[3].
Generic Market Dynamics
Generic drugs like Hydralazine Hydrochloride play a crucial role in the pharmaceutical market due to their affordability and widespread use. The generic market is highly competitive, with multiple manufacturers often producing the same drug. This competition can lead to price reductions and increased accessibility for patients.
Pricing Mechanisms
Wholesale Acquisition Cost (WAC)
The pricing of generic drugs is often determined by the Wholesale Acquisition Cost (WAC), which is the list price at which wholesalers purchase the drug from the manufacturer. For Hydralazine Hydrochloride, the WAC can vary depending on the package size and formulation.
Price Comparisons and Reductions
In the generic drug market, prices can fluctuate based on market competition and regulatory factors. For example, Dr. Reddy’s Laboratories introduced a generic version of Lenalidomide, which resulted in a 14% reduction in the WAC price compared to the branded version, Revlimid[2]. Similar competitive dynamics could influence the pricing of Hydralazine Hydrochloride.
Price Projections
Current Pricing
As of the latest available data, the pricing for Hydralazine Hydrochloride (NDC 23155-0832) would typically be found in pharmacy pricing databases or through direct inquiries with the manufacturer or wholesalers. However, without current specific pricing data, we can infer that the price would be competitive with other generic versions of Hydralazine Hydrochloride on the market.
Future Pricing Trends
Given the competitive nature of the generic drug market, here are some potential trends that could influence future pricing:
- Competition and Market Entry: New entrants into the market could lead to price reductions as manufacturers compete for market share.
- Regulatory Changes: Changes in regulatory requirements or policies could affect the production costs and subsequently the pricing of the drug.
- Economic Factors: Economic conditions, such as inflation or changes in raw material costs, can impact the pricing of pharmaceuticals.
Example Pricing Scenario
While specific future pricing data is not available, here is a hypothetical scenario based on industry trends:
- If the current WAC for Hydralazine Hydrochloride is around $10 per unit, increased competition could lead to a reduction of 5-10% over the next year.
- Regulatory changes or economic factors might stabilize prices or lead to slight increases, but these would likely be minimal given the generic nature of the drug.
Market Analysis
Demand and Supply
The demand for Hydralazine Hydrochloride is driven by its use in treating hypertension and heart failure. The supply is influenced by the number of manufacturers producing the drug and their production capacities.
Competitive Landscape
The competitive landscape for Hydralazine Hydrochloride includes other generic manufacturers as well as any remaining branded versions. Heritage Pharmaceuticals Inc. (d/b/a Avet Pharmaceuticals Inc.) is one of the players in this market, and their pricing strategy would need to be competitive to maintain market share.
Key Takeaways
- Generic Competition: The pricing of Hydralazine Hydrochloride is heavily influenced by competition within the generic drug market.
- Regulatory and Economic Factors: Changes in regulations or economic conditions can impact production costs and pricing.
- Market Trends: The overall pharmaceutical market trends, including shifts towards patient-centered care and technological advancements, can indirectly influence the pricing and availability of generic drugs.
FAQs
What is the NDC 23155-0832 used for?
The NDC 23155-0832 corresponds to Hydralazine Hydrochloride, which is used to treat high blood pressure (hypertension) and certain cases of heart failure.
Who manufactures NDC 23155-0832?
NDC 23155-0832 is manufactured and distributed by Heritage Pharmaceuticals Inc., doing business as Avet Pharmaceuticals Inc.
How is the pricing of generic drugs like Hydralazine Hydrochloride determined?
The pricing of generic drugs like Hydralazine Hydrochloride is typically determined by the Wholesale Acquisition Cost (WAC), which can be influenced by market competition, regulatory changes, and economic factors.
What are the potential future pricing trends for Hydralazine Hydrochloride?
Future pricing trends could include reductions due to increased competition, stabilization due to regulatory changes, or slight increases due to economic factors.
How does the competitive landscape affect the pricing of Hydralazine Hydrochloride?
The competitive landscape, which includes multiple generic manufacturers, drives the pricing of Hydralazine Hydrochloride. Manufacturers must set competitive prices to maintain market share.
What role do regulatory changes play in the pricing of generic drugs?
Regulatory changes can affect production costs and subsequently the pricing of generic drugs. Compliance with regulatory requirements is crucial for maintaining market presence.
Sources
-
National Drug Code Database Background Information - FDA:
-
New Prescription Drug Price Reporting:
-
5 Predictions for the Biopharma and Biotech Industries in 2025:
-
NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025:
-
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.:
